title: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
abstract: An active specific immunization (ASI) procedure with two types of autologous tumor cell vaccines (ATVs) is tested for adjuvant immunotherapy of resected colorectal carcinoma to provide preliminary information on local immunological skin responses, side effects, and 2-year survival rates. For vaccine preparation, the tumor-derived freshly isolated and cryopreserved cells were thawed, purified by Percoll density centrifugation, and depleted of tumor-infiltrating lymphocytes by immunomagnetic beads. After inactivation by 200 Gy, the cells of this ATV were either infected by Newcastle disease virus (NDV) or they were admixed with Bacillus Calmette Guérin (BCG) organisms. Vaccination was performed in the arm beginning 6-8 weeks after operation, three times at 2-week intervals. Of 57 patients that received ASI, 48 were treated by virus-infected ATV (ATV-NDV) and 9 were treated with the BCG-admixed vaccine (ATV/BCG). The mean value of delayed hypersensitivity skin reactions from ATV-NDV-treated patients was 18 mm for the first vaccination and 26 and 29 mm for the succeeding ones. Although the application of ATV-NDV was associated with only mild side effects, the ATV/BCG vaccine led to long-lasting ulcers and to more serious side effects. The 2-year survival rate obtained with ATV-NDV was 97.9%, whereas the survival rate with ATV/BCG was 66.7%. The mean survival of 661 patients from a historical control was 73.8%. These data suggest that the type and quality of the tumor vaccine for ASI treatment is important. The findings with ATV-NDV necessitate corroboration in a prospective, randomized controlled study.
authors.affiliation: Surgical Department, University Hospital, Mannheim, Gynecology Department, University Hospital, Heidelberg, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Ockert
authors.forename: V
authors.initials: V
authors.lastname: Schirrmacher
authors.forename: N
authors.initials: N
authors.lastname: Beck
authors.forename: E
authors.initials: E
authors.lastname: Stoelben
authors.forename: T
authors.initials: T
authors.lastname: Ahlert
authors.forename: J
authors.initials: J
authors.lastname: Flechtenmacher
authors.forename: E
authors.initials: E
authors.lastname: Hagmüller
authors.forename: R
authors.initials: R
authors.lastname: Buchcik
authors.forename: M
authors.initials: M
authors.lastname: Nagel
authors.forename: H D
authors.initials: HD
authors.lastname: Saeger
mesh_terms: D000368:Aged; D019496:Cancer Vaccines / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D016233:Immunotherapy, Active / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009522:Newcastle disease virus / Q000276:immunology*; D015996:Survival Rate
chemical_list: D019496:Cancer Vaccines